Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Company Overview
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of novel therapeutic candidates. The company is strategically positioned in the fields of immunology, inflammation, and oncology, utilizing an asset-rich in-licensing model that leverages the deep experience of its founding team. This approach focuses on targeting high unmet needs among patient populations with conditions that are complex and challenging to manage, ensuring that Gossamer Bio remains relevant in addressing critical healthcare issues.
Core Business Areas
The company’s operations are centered on identifying and advancing therapeutic candidates that address key disease mechanisms such as cellular overgrowth, fibrosis, and dysregulated vascular remodeling. By focusing on immunology, inflammation, and oncology, Gossamer Bio develops treatments aimed at conditions including pulmonary arterial hypertension, inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, specific oncology indications, and moderate-to-severe respiratory conditions such as eosinophilic asthma. Its expert research and development team capitalizes on proven methodologies in drug discovery, ensuring that each candidate is backed by comprehensive preclinical and clinical evaluation.
Gossamer Bio reported its financial results for Q4 and full year 2022, highlighting a net loss of $55.8 million or $0.59 per share in Q4, and a full-year net loss of $229.4 million or $2.71 per share. Cash, cash equivalents, and marketable securities were $256 million, expected to sustain operations into the second half of 2024. The company plans to initiate a Phase 3 clinical trial for Seralutinib (GB002) in pulmonary arterial hypertension in H2 2023, while enrollment in the Phase 1b/2 GB5121 CNS study is paused.
Gossamer Bio announced promising topline results from the TORREY Phase 2 study of seralutinib in treating pulmonary arterial hypertension (PAH). The primary endpoint, change in pulmonary vascular resistance (PVR) at Week 24, was met with a statistically significant P-value of 0.0310. Secondary endpoints also favored seralutinib, particularly in patients classified as WHO Functional Class III, showing a 21% reduction in PVR and a 37-meter improvement in six-minute walk distance (6MWD). Seralutinib exhibited a favorable safety profile, with most adverse events being mild to moderate.
Gossamer Bio reported its financial results for Q3 2022, highlighting a cash position of $304.4 million as of September 30, 2022. The Phase 2 TORREY Study for Seralutinib, targeting pulmonary arterial hypertension, is on schedule for topline results by December 2022. R&D expenses rose to $44.5 million from $43.2 million year-over-year, while G&A expenses decreased to $11.5 million. The net loss narrowed to $59.4 million or $0.65 per share compared to the previous year. Gossamer expects existing resources to fund operations into Q2 2024.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported financial results for Q2 2022, highlighting a net loss of $56.5 million ($0.74 per share), improved from $59.8 million ($0.80 per share) in Q2 2021. As of June 30, 2022, the company had $342 million in cash and equivalents, bolstered by a $120 million private placement in July 2022. Upcoming milestones include topline data from the Phase 2 TORREY Study on seralutinib, expected by year-end, and the initiation of a Phase 3 clinical program in Q3 2023. Additionally, the first patient has been dosed in the Phase 1b/2 STAR CNS Study for GB5121.
Gossamer Bio, Inc. (NASDAQ: GOSS) announced a private placement of approximately 16.6 million shares at $7.21 each, expecting gross proceeds of around $120 million before expenses. This financing, closing on July 15, 2022, involves new and existing institutional investors, all participating under lock-up agreements. The funds will support the seralutinib program and other R&D efforts, with sufficient funds anticipated to cover operating expenses into mid-2024. The company plans to file for resale registration with the SEC, as the shares have not been registered under the Securities Act.
Gossamer Bio, Inc. (NASDAQ: GOSS) announces the publication of preclinical data on seralutinib for pulmonary arterial hypertension (PAH) in the European Respiratory Journal. The article highlights seralutinib's potential efficacy in treating PAH, with expectations for topline results from the Phase 2 TORREY Study to be released in Q4 this year. CEO Faheem Hasnain expressed enthusiasm for the recognition of their work in a prestigious journal, signaling a pivotal moment for the company's ongoing research.
Gossamer Bio announced the completion of patient enrollment in the Phase 2 TORREY Study for Seralutinib (GB002), targeting pulmonary arterial hypertension. Topline results are expected in Q4 2022. As of March 31, 2022, Gossamer reported cash, cash equivalents, and marketable securities of
Gossamer Bio announced the termination of its Phase 2 SHIFT-UC Study of GB004 for ulcerative colitis, as neither treatment arm met primary or secondary endpoints at week 12. The study enrolled 236 participants but showed no meaningful clinical benefit. However, Gossamer is advancing its Phase 2 TORREY Study of seralutinib in pulmonary arterial hypertension, with topline results expected in Q4 2022. As of March 31, 2022, Gossamer reported approximately $272 million in cash, cash equivalents, and marketable securities.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio's core business focus?
How does Gossamer Bio generate revenue?
What therapeutic areas does the company target?
How does the company differentiate itself from competitors?
What is the significance of focusing on high unmet needs?
What role does the company’s clinical-stage status play in its operations?
